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Abstract
Background: Disrupted cholesterol regulation leading to increased circulating and membrane cholesterol levels is 
implicated in many age-related chronic diseases such as cardiovascular disease (CVD), Alzheimer's disease (AD), and 
cancer. In vitro and ex vivo cellular plasmalogen deficiency models have been shown to exhibit impaired intra- and 
extra-cellular processing of cholesterol. Furthermore, depleted brain plasmalogens have been implicated in AD and 
serum plasmalogen deficiencies have been linked to AD, CVD, and cancer.
Results: Using plasmalogen deficient (NRel-4) and plasmalogen sufficient (HEK293) cells we investigated the effect of 
species-dependent plasmalogen restoration/augmentation on membrane cholesterol processing. The results of these 
studies indicate that the esterification of cholesterol is dependent upon the amount of polyunsaturated fatty acid 
(PUFA)-containing ethanolamine plasmalogen (PlsEtn) present in the membrane. We further elucidate that the 
concentration-dependent increase in esterified cholesterol observed with PUFA-PlsEtn was due to a concentration-
dependent increase in sterol-O-acyltransferase-1 (SOAT1) levels, an observation not reproduced by 3-hydroxy-3-
methyl-glutaryl-CoA (HMG-CoA) reductase inhibition.
Conclusion: The present study describes a novel mechanism of cholesterol regulation that is consistent with clinical 
and epidemiological studies of cholesterol, aging and disease. Specifically, the present study describes how selective 
membrane PUFA-PlsEtn enhancement can be achieved using 1-alkyl-2-PUFA glycerols and through this action reduce 
levels of total and free cholesterol in cells.
Background
A breakdown in cholesterol homeostasis has adverse
effects at the cellular level, as well as in the context of the
organism. Altered cholesterol content in cells affects
membrane fluidity, which has drastic effects on cellular
function, signal transduction, and intercellular communi-
cation events [1,2]. Elevated levels of circulating choles-
terol have been linked with the formation of
atherosclerotic plaques, and is a risk factor for cerebro-
vascular lesions and coronary heart disease [3,4]. Apoli-
poprotein E4 (ApoE4), a vehicle for cholesterol transport,
is a major risk factor for sporadic Alzheimer's disease
(AD), demonstrating a link between cholesterol and cog-
nition [5]. Increase in cholesterol in tumor tissue is a
common underlying feature in a number of cancers;
safety data from randomized clinical trials of cholesterol
lowering statins demonstrated lower incidences of mela-
noma, colorectal, breast and prostate cancers, reviewed
by Hager and coworkers [6].
Cholesterol exists in two mutually exclusive pools in
the body separated by the blood brain barrier. Within
each pool it can be found either in a free (unesterified)
state, or it can exist as esters. Brain cholesterol is synthe-
sized de novo, and accounts for 25% of the total body cho-
lesterol, wherein it exists primarily as free cholesterol in
myelin and the plasma membranes of glial cells and neu-
rons [7,8]. The remaining cholesterol is accounted for in
tissues and in circulation. The plasma membrane of cells
is predominantly composed of unesterified cholesterol,
which is enriched in microdomains called lipid rafts, key
structural requirements for signal transduction. Circulating
cholesterol on the other hand is coupled with lipoproteins
(chylomicrons, VLDL, LDL and HDL). Chylomicrons,
VLDL and LDL serve as vehicles for the movement of
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Page 2 of 17dietary cholesterol to the liver for removal from circula-
tion. HDL, synthesized by the liver and intestine, is the
vehicle for the transport of tissue cholesterol to the liver
for excretion, a process called reverse cholesterol trans-
port (reviewed by Martins and coworkers) [9].
Plasmalogens are a class of glycerophospholipids char-
acterized by a vinyl-ether linkage at the sn-1 position and
an acyl linkage at the sn-2 position of the glycerol back-
bone. Besides contributing to membrane structural integ-
rity, plasmalogens are involved in multiple cellular
functions such as vesicle formation and membrane fusion
[10-12], ion transport [13-15] and generation of second-
ary signal mediators such as platelet activating factor
(PAF) [16,17]. Presence of the vinyl ether bond imparts
antioxidant properties to these molecules which miti-
gates free radical based cellular damage [18-21].
The multitude of functions attributed to this class of
molecules implicates it in a number of human disorders
ranging from peroxisomal disorders such as Zellwegger
syndrome, rhizomelic chondrodysplasia punctata
(RCDP), infantile Refsum disease and cholesterol storage
disorders such as Neiman-Pick type C disease to Down's
syndrome and Alzheimer's disease [22-28]; Ethanolamine
plasmalogen depletion has been observed in post-mor-
tem brains of AD subjects [29,30] and in the serum of
subjects suffering from AD [31], cardiovascular disease
[32], and cancer [33]
Studies have shown that brain and circulating plasmal-
ogens negatively correlate with age [34-36]. Additionally,
plasmalogens have been linked with altered cholesterol
processing [37-39]; a plasmalogen-deficient cell exhibits
lower esterified cholesterol and a lower rate of HDL-
mediated cholesterol efflux. Meaba and coworkers
recently showed a link between plasmalogens and Apo
A1 and A2, the major components of HDL [35].
These observations prompted us to investigate the rela-
tionship between membrane plasmalogen level and cho-
lesterol regulation using both plasmalogen deficient
(NRel-4) and sufficient (HEK293) cell lines. A novel spe-
cies-specific plasmalogen restorative/augmentation
approach was applied to both cell types and the resulting
effect on cholesterol (total, esterified, and free) and ste-
rol-O-acyltransferase-1 (SOAT1 encodes acyl-coenzyme
A:cholesterol acyl transferase, ACAT, a critical mem-
brane bound cholesterol processing enzyme), levels
ascertained. This report identifies the use of plasmalo-
gens in achieving cholesterol homeostasis as an alterna-
tive to statin therapy.
Materials and Methods
Syntheses of Compounds for Structure Activity 
Relationship Study
The compounds used for this structure activity relation-
ship study were synthesized from readily available start-
ing materials as shown in the synthetic scheme (Figure 1)
and in Table 1.
General Methods
All chemicals and solvents were purchased from Sigma-
Aldrich Canada Ltd., Oakville, ON., VWR Canada and
Nu-Chek Prep., Elysian, MN. All solvents used were
anhydrous. Analytical thin layer chromatography (TLC)
was carried out on precoated silica gel TLC aluminum
sheets (EM science, Kieselgel 60 F254, 5 × 2 cm × 0.2 mm).
Compounds were visualized under UV light (254/366
nm) or placed in iodine vapor tank and by dipping the
plates in a 5% aqueous (w/v) phosphomolybdic acid solu-
tion containing 1% (w/v) ceric sulfate and 4% (v/v) H2SO4,
followed by heating. Flash column chromatography was
carried out using silica gel, Merck grade 60, mesh size
230-400, 60 Å. NMR spectra were recorded on Bruker
Avance spectrometers; for 1H (500 MHz), δ values were
referenced to CDCl3 (CHCl3 at 7.24 ppm) and for 13C
NMR (125.8 MHz) referenced to CDCl3 (77.23 ppm).
Coupling constants (J) are reported to the nearest 0.5 Hz.
High resolution mass spectral data were obtained on
Bruker Apex 7T Fourier transform ion cyclotron reso-
nance mass spectrometer (FT-ICRMS) with atmospheric
pressure chemical ionization in the positive mode
(HRAPCI-MS). MS/MS data collected using QStar XL
TOF mass spectrometer with atmospheric pressure
chemical ionization (APCI) source in the positive mode
and collision energy of 20 and 35 V. Fourier transform
infra-red (FTIR) spectra were recorded on Bio-Rad FTS-
40 spectrometer using the diffuse reflectance method on
samples dispersed in KBr. Refer synthetic scheme (Figure
1) and Table 1 for details of compounds synthesized.
Figure 1 Scheme showing the syntheses of phosphoetha-
nolamine plasmalogen precursors C1-3, C6-10, and diacylglycer-
ols C4 and C5, test compounds for the study. Reagents: (a) i R1Br, 
NaH/DMF or R1SO4CH3, NaH/THF, reflux; (ii) 10% HCl, reflux; (b) TBDMS-
Cl, imidazole/DMF; (c) R2COCl, DMAP, Pyridine, Toluene; (d) TBAF/THF, 
Imidazole, - 20°C
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To sodium hydride (1.85 g, 60% dispersed in mineral oil)
under argon was added anhydrous N, N-dimethylforma-
mide (DMF, 10 ml) at room temperature (RT). Solketal
(16.7 mmol) in 10 ml anhydrous DMF was then added
dropwise with constant stirring. 1-Bromohexadecane, 1-
bromooctadecane or octadec-9-enylmethane sulphonate
(16.7 mmol) [40,41] dissolved in anhydrous DMF (10 ml)
was then added to the reaction mixture dropwise and
stirred for 48 hours. The reaction mixture was poured
into cold ice water (100 ml) and extracted with hexane
(100 ml, 3×). After drying over anhydrous Na2SO4 and
removal of solvent, the crude product was treated with
10% HCl solution (40 ml) and refluxed at 120°C for 30
min. The reaction mixture was then kept at RT for 24
hours. The off white lumps and the mother liquor was
extracted with diethylether (100 ml, 3×) washed succes-
sively with saturated aqueous NaHCO3 (100 ml) and
water (100 ml), dried over anhydrous Na2SO4 and the sol-
vent removed under reduced pressure to obtain the prod-
ucts C11-13. Satisfactory spectral and analytical data
were obtained [42].
General procedure for synthesis of C14-18
Each of compounds C11-13, monopalmitin and monos-
tearin (1.63 mmol) was dissolved separately in anhydrous
DMF (2.00 ml) followed by the addition of imidazole
(3.72 mmol) and tert-butyl dimethylsilyl chloride (1.88
mmol). The reaction mixture was stirred at RT for 24
hours, poured into water (100 ml) and extracted with
diethyl ether (100 ml, 3×). After removal of solvent, the
crude product was chromatographed on silica gel using
CH2Cl2-MeOH to obtain the products [43].
General procedure for synthesis of C19-28
To a mixture of each of C14-18 (0.578 mmol), anhydrous
pyridine (0.35 ml), catalytic amount of dimethylamin-
opyridine (0.100 mmol) and toluene (5 ml) was added the
appropriate acyl chloride like (4Z,7Z,10Z,13Z,16Z,19Z)-
docosa-4,7,10,13,16,19-hexaenoyl chloride (0.576 mmol)
dropwise under argon and stirred at RT for 48 hours. The
reaction mixture was poured into water (100 ml),
extracted with diethyl ether (100 ml, 3×), washed succes-
sively with 0.25 M H2SO4 solution (100 ml), saturated
aqueous NaHCO3 (100 ml) and water (100 ml). After dry-
ing over anhydrous Na2SO4 and removal of solvent, the
crude product was subjected to chromatography on silica
gel using hexane-CH2Cl2 mixtures to obtain the products.
General procedure for synthesis of C1-10
To a mixture of each of C19-28 (0.272 mmol) and THF (2
ml) was added imidazole (0.942 mmol) and 0.80 ml of 1.0
Table 1: List of compounds synthesized for the SAR study.
Compound sn-1 (R1) sn-2 (R2) sn-3
1 cis-(±)-2-O-docosahexaenoyl-1-O-hexadecylglycerol 16:0 (alkyl) DHA OH
2 cis-(±)-2-O-docosahexaenoyl-1-O-octadecylglycerol 18:0 (alkyl) DHA OH
3 cis-(±)-2-O-docosahexaenoyl-1-O-octadec-9-enylglycerol 18:1 (alkyl) DHA OH
4 cis-(±)-2-O-docosahexaenoyl-1-O-palmitoylglycerol 16:0 (acyl) DHA OH
5 cis-(±)-2-O-docosahexaenoyl-1-O-stearoylglycerol 18:0 (acyl) DHA OH
6 cis-(±)-2-O-stearoyl-1-O-hexadecylglycerol 16:0 (alkyl) 18:0 OH
7 cis-(±)-2-O-oleoyl-1-O-hexadecylglycerol 16:0 (alkyl) 18:1 OH
8 cis-(±)-2-O-linoleoyl-1-O-hexadecylglycerol 16:0 (alkyl) 18:2 OH
9 cis-(±)-2-O-α-linolenoyl-1-O-hexadecylglycerol 16:0 (alkyl) 18:3 OH
10 cis-(±)-2-O-arachidonoyl-1-O-hexadecylglycerol 16:0 (alkyl) 20:4 OH
All molecules had a glycerol backbone, and differed in the sn-1 and sn-2 fatty acid acids. The sn-1 fatty acid was linked to glycerol either by an 
alkyl or acyl linkage.
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perature for 24 hours with constant stirring. The reaction
mixture was then passed through a plug of silica gel and
eluted with cold diethylether (10 ml, - 20°C). After
removal of solvent, the crude products were chromato-
graphed on silica gel using hexane - ethyl acetate mix-
tures to obtain the products [44,45].
Spectral data for cis-(±)-2-O-Docosahexaenoyl-1-O-
hexadecylglycerol (C1)
Obtained from C19, as light yellow oil; 144.6 mg (67%);
TLC: Rf = 0.65 (CH2Cl2:MeOH, 95:5 v/v); 1H NMR
(CDCl3): δ in ppm 0.86 (3H, t, J = 7.0 Hz), 0.95 (3H, t, J =
7.0 Hz), 1.23-1.27 (24H, m), 1.52-1.56 (4H, m), 2.06 (2H,
m), 2.17 (1H, br s), 2.38-2.41 (4H, m), 2.79-2.82 (10H, m),
3.38-3.47 (2H, m), 3.56-3.63 (2H, m), 3.76-3.79 (2H, m),
4.98 (1H, quintet, J = 5.0 Hz), 5.33-5.38 (12H, m); 13C
NMR (CDCl3): δ in ppm 14.3, 14.5, 20.8, 22.9, 23.0, 25.8,
25.9, 26.3, 29.6, 29.7, 29.8 (3), 29.9, 32.1, 34.5, 63.2, 70.1,
72.1, 73.3, 127.2, 128.0, 128.1, 128.2, 128.3 (2), 128.5 (3),
128.8, 129.6, 132.3, 173.1; FT-IR (cm-1) 3401 (br), 2931,
2850, 1728; HRAPCI-MS m/z: measured 627.5353 ([M +
H]+, calcd. 627.5352 for C41H71O4); APCI-MS/MS m/z:
627 ([M + H]+, 80%), 609 (20%), 385 (40%), 329 (15%), 311
(100%), 293 (90%), 269 (35%), 75 (70%).
Spectral data for cis-(±)-2-O-Docosahexaenoyl-1-O-
octadecylglycerol (C2)
Obtained from C20, as light yellow oil; 75.2 mg (66.3%);
TLC: Rf = 0.80 (CH2Cl2:MeOH, 95:5 v/v); 1H NMR
(CDCl3): δ in ppm 0.86 (3H, t, J = 7.0 Hz), 0.95 (3H, t, J =
7.0 Hz), 1.23-1.27 (28H, m), 1.50-1.56 (4H, m), 2.05 (2H,
m), 2.19 (1H, br s), 2.37-2.42 (4H, m), 2.78-2.83 (10H, m),
3.38-3.46 (2H, m), 3.55-3.63 (2H, m), 3.76-3.79 (2H, m),
4.98 (1H, quintet, J = 5.0 Hz), 5.33-5.38 (12H, m); 13C
NMR (CDCl3): δ in ppm 14.3, 14.5, 20.8, 22.9, 23.0, 25.8
(2), 25.9, 26.3, 29.6, 29.7, 29.8 (3), 29.9, 32.1, 34.5, 63.2,
70.1, 72.1, 73.3, 127.2, 128.0, 128.1, 128.2, 128.3 (2), 128.5
(3), 128.8, 129.6, 132.3, 173.1; FT-IR (cm-1) 3397 (br),
2954, 2861, 1738.; HRAPCI-MS m/z: measured 655.5665
([M + H]+, calcd. 655.5665 for C43H75O4); APCI-MS/MS
m/z: 655 ([M + H]+ 75%), 637 (30%), 385 (40%), 329 (15%),
311 (100%), 293 (60%), 269 (20%), 75 (60%).
Spectral data for cis-(±)-2-O-Docosahexaenoyl-1-O-octadec-
9-enylglycerol (C3)
Obtained from C21, as light yellow oil; 62.4 mg (61.3%);
TLC: Rf = 0.75 (CH2Cl2:MeOH, 95:5 v/v); 1H NMR (in
CDCl3): δ in ppm 0.86 (3H, t, J = 7.0 Hz), 0.94 (3H, t, J =
7.5 Hz), 1.25-1.29 (20H, m), 1.51-1.55 (4H, m), 1.99-2.07
(6H, m), 2.15 (1H, br s), 2.40-2.45 (4H, m), 2.77-2.83
(10H, m), 3.40-3.45 (2H, m), 3.53-3.64 (2H, m), 3.77-3.78
(2H, m), 4.98 (1H, quintet, J = 5.0 Hz), 5.33-5.36 (14H, m);
13C NMR (in CDCl3): δ in ppm 14.3, 14.4, 20.7, 22.7, 22.8,
25.7, 25.8 (2), 26.2, 27.4, 29.4, 29.5, 29.6 (2), 29.7, 29.9 (3),
32.1, 34.1, 64.3, 70.8, 72.0, 72.5, 127.2, 127.9, 128.0, 128.2,
128.3 (2), 128.4 (2), 128.5, 128.7, 129.7, 129.9, 130.1,
132.2, 173.1; FT-IR (cm-1) 3385 (br), 2917, 2852, 1722;
HRAPCI-MS m/z: measured 653.5509 ([M + H]+, calcd.
653.5509 for C43H73O4); APCI-MS/MS m/z: 653 ([M +
H]+ 70%), 635 (30%), 385 (35%), 329 (15%), 311 (100%),
293 (65%), 269 (20%), 97 (30%).
Cell lines
HEK 293 cells were purchased from ATCC, and cultured
in DMEM, 10% FBS at 37°C, 5% CO2. CHO and NRel-4
cells were a kind gift from Dr. R.A. Zoeller (Boston Uni-
versity) and were cultured in F-12 medium, 10% FBS at
37°C, 5% CO2. NRel-4 cells are deficient in peroxisomal
dihydroxyacetonephosphate acyltransferase (DHAPAT;
EC 2.3.1.42; Figure 2).
Q-TRAP analysis
The plasmalogen-deficient CHO cell line (NRel-4) was
used to assay the efficacy of test compounds C1-10 in
plasmalogen restoration. CHO (wild type) or NRel-4
(plasmalogen deficient) cells were seeded in DMEM/F-12
medium (10% FBS) on a 10 cm dish the day before the
experiment. The following day, the media was replaced
with fresh media containing the test compound or the
solvent ethanol (0.1% V/V) as a control [46]. Cells were
cultured for 72 hours at 37°C, 5% CO2, after which they
were harvested using Versene/TrypLE express (Gibco
Life Technology, Rockville, MD). The cell pellet was
washed with phosphate buffered saline (PBS, pH 7.4), and
the phospholipids were extracted and analyzed using a
linear ion-trap mass spectrometer coupled to a LC sys-
tem as described [31].
Cholesterol Assay
Human embryonic kidney 293 (HEK293) cells and CHO/
NRel-4 cells were seeded the day before the treatment.
The following day, the cells were treated with the test
compounds C1-10 or with ethanol as the control. Con-
centrations used for pravastatin, clofibrate, and troglita-
zone treatments were as described [47-49]. Cells were
harvested after 48 hours using Versene: TryPLe express
cocktail, washed with PBS. Lipids were extracted with
chloroform containing 1%Triton X-100. The organic frac-
tion was recovered and dried under a stream of nitrogen.
The dried lipids were resuspended in cholesterol reaction
buffer (Biovision, Mountain View, CA), and the total, free
and esterified fractions of cholesterol were quantified
using the cholesterol quantification kit (Biovision, Moun-
tain View, CA) as per the manufacturer's recommenda-
tions. Cholesterol was reported as μg/million cells.
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Figure 2 Relative ethanolamine plasmalogens in DHAPAT-deficient cells (A). Plasmalogen content of CHO (C_V) and NRel-4 (N_V) cell lines. Val-
ues are an average of three independent experiments; error bars represent standard deviation. All transitions measured in NRel-4 cells were signifi-
cantly different from control cells (p < 0.05). Cholesterol profile of DHAPAT-deficient cells (B). Values are an average of independent experiments; error 
bars represent standard deviation. Total, free and esterified cholesterol of N_V is significantly different from C_V ( p < 0.05).
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HEK293 cells were treated as described in the amyloid
assay. The cell pellet was washed in PBS and lysed in
RIPA buffer containing a protease inhibitor cocktail
(Sigma, St. Louis, MI). Protein in the cell lysate was quan-
tified using the Bio-Rad Protein Assay (Bio-Rad, Hercu-
les, CA). The following antibodies were used for western
analyses: SOAT1 (Santa Cruz Biotechnology Inc., CA)
and β-actin (Sigma, St. Louis, MI). Band intensities were
calculated using ImageJ (National Institutes of Health).
Statistical analysis
Statistical Analysis of the data was performed using
Microsoft Office Excel 2007 and JMP version 8. Multiple
comparison Dunnett's tests were applied to analyze the
differences between the treatments and the control.
Results
The Effect of Plasmalogen Deficiency on Membrane 
Cholesterol Composition
Membrane plasmalogen levels of NRel-4 cells, lacking
dihydroxyacetone phosphate acyl transferase (DHAPAT),
an obligate enzyme in the plasmalogen biosynthesis path-
way [50,51], were less than 10% of wild-type CHO cells (
Table 2 and Figure 2A) as assessed through the relative
quantification of five common palmityl ether etha-
nolamine plasmalogens (PlsEtn). The cell membranes of
NRel-4 cells also contained nearly 2-fold more free cho-
lesterol (Figure 2B) and 4-fold less esterified cholesterol
than CHO cells (Figure 2C).
The Effect of Plasmalogen Precursor sn-1 and sn-2 
Substituents on Plasmalogen Composition in CHO and 
NRel-4 Cells
Using wild CHO and NRel-4 cells, side chain-specific
PlsEtn and phosphatidylethanolamine (PtdEtn) precur-
sors (Table 1) were evaluated for their abilities to aug-
ment cellular plasmalogen levels in control (CHO) and
PlsEtn-deficient (NRel-4) cells. These alkylacylglyceryl
ethers bypass the requirement for peroxisomes in the
synthesis of plasmalogens (Figure 3). The following
observations were made:
1. Maintaining the free alcohol at sn-3 and DHA at sn-
2, PlsEtn precursors C1-3 with differing long chain 
ether substitutions at sn-1 revealed that these precur-
sor compounds either partially or fully restored all 
ethanolamine plasmalogens with the same sn-1 alkyl 
ether but had no effect on PlsEtn with different sn-1 
compositions (Figure 4). For example, treatment with 
a palmityl PlsEtn precursor (C1) restored the down-
stream pool of 16:0 ethanolamine plasmalogens with 
no effect on the 18:0 and 18:1 PlsEtn pools. Such side 
chain-specific restoration indicates that no rearrange-
ment of the sn-1 moiety (O-alkyl linkage) occurs, 
while the sn-2 moiety is able to undergo deacylation 
and subsequent reacylation with other fatty acid resi-
dues.
2. Similarly, compounds C6-C10 (16:0 at sn-1 but dif-
fering at the sn-2 substituent) significantly elevate the 
16:0 pool, with no effect on the 18:0 and 18:1 pools of 
PlsEtn (Figure 4).
3. Distribution of PlsEtn within a pool (16:0, 18:0 or 
18:1) depends on the fatty acid at sn-1 position. C1 
and C3 showed maximum restoration of the PlsEtn 
directly downstream in the pathway (16:0/22:6 PlsEtn 
and 18:1/22:6 PlsEtn respectively). C2 on the other 
hand significantly augments all PlsEtns in the 18:0 
pool (Figure 5).
4. Comparison of compounds C1, C6-10, revealed 
that whereas DHA containing precursors can par-
tially or fully restore all other sn-2 PlsEtn, non-DHA 
containing precursors cannot completely restore 
DHA-PlsEtn (Figure 6A).
5. DHA-PtdEtn precursors (C4 and C5) cannot 
restore DHA-PlsEtn deficiencies (Figure 6B).
6. PlsEtn precursors with DHA at sn-2 concentration-
dependently increase DHA-PlsEtn in both DHAPAT 
deficient cells (NRel-4) and wild-type cells (CHO) 
(Figure 7A). However, with respect to total plasmalo-
gen content, only the deficient cell line showed an 
increase; no augmentation in total plasmalogen con-
tent was observed in wild-type CHO cells (Figure 7B).
The Effect of Plasmalogen Precursor Structure on 
Membrane Cholesterol Composition
As demonstrated above, plasmalogen deficient cells have
higher content of free cholesterol and lower amounts of
esterified cholesterol in their cell membranes. To deter-
mine whether this effect was due to a general decrease in
membrane PlsEtn composition or to decreased levels of
specific PlsEtn, membrane PlsEtn levels in PlsEtn
depleted cells (NRel-4) were selectively restored as
described above and the corresponding effect on mem-
brane cholesterol composition ascertained. The key
observations were:
1. PtdEtn precursors (C4 and C5) had no effect, while 
PlsEtn precursors with < 3 unsaturations (C7 and C8) 
had a mild effect on membrane cholesterol composi-
tion (Figure 8).
2. PlsEtn precursors with 3 or more unsaturations 
(C1, C9 and C10) had a more profound effect on 
reducing free cholesterol (Figure 8B) and increasing 
esterified cholesterol (Figure 8C).
The effect of plasmalogen precursors and other com-
pounds on membrane cholesterol composition was fur-
ther studied in PlsEtn normal human HEK293 cells
(Figure 9). The key observations were:
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dependent decrease in free cholesterol (47% at 20 
μM) (Figure 9B) and a reciprocal increase in the ester-
ified fraction of cholesterol (31% at 20 μM) (Figure 
9C)
2. PtdEtn precursors (C4 and C5) had no effect on 
free cholesterol and resulted in slight decreases in 
esterified cholesterol.
3. PlsEtn precursors with sn-2 substituents containing 
< 3 unsaturations (C6, C7 and C8) either elevated or 
had no effect on free cholesterol.
4. PlsEtn precursors with sn-2 substituents containing 
3 or more unsaturations either reduced free choles-
terol (C1 and C9) and/or increased esterified choles-
terol (C1 and C10).
Table 2: Ethanolamine plasmalogen distribution in cell lines
Absolute Signal CHO NRel-4 HEK293
PlsEtn 16:0/18:1 4.935 (11.6) 0.385 (9.2) 5.860 (13.7)
PlsEtn 16:0/18:2 4.650 (10.9) 0.405 (9.7) 0.944 (2.2)
PlsEtn 16:0/18:3 0.069 (0.2) 0.008 (0.2) 0.127 (0.3)
PlsEtn 16:0/20:4 5.900 (13.8) 0.997 (23.9) 9.053 (21.1)
PlsEtn 16:0/22:6 0.442 (1.0) 0.093 (2.2) 2.737 (6.4)
PlsEtn 18:0/18:1 3.580 (8.4) 0.273 (6.5) 2.840 (6.6)
PlsEtn 18:0/18:2 4.155 (9.7) 0.312 (7.5) 0.556 (1.3)
PlsEtn 18:0/18:3 0.059 (0.1) 0.004 (0.1) 0.072 (0.2)
PlsEtn 18:0/20:4 6.300 (14.8) 0.660 (15.8) 5.780 (13.5)
PlsEtn 18:0/22:6 0.491 (1.1) 0.104 (2.5) 1.787 (4.2)
PlsEtn 18:1/18:1 3.805 (8.9) 0.213 (5.1) 4.227 (9.9)
PlsEtn 18:1/18:2 3.390 (7.9) 0.185 (4.4) 0.623 (1.5)
PlsEtn 18:1/18:3 0.065 (0.2) 0.003 (0.1) 0.078 (0.2)
PlsEtn 18:1/20:4 4.390 (10.3) 0.485 (11.6) 6.170 (14.4)
PlsEtn 18:1/22:6 0.431 (1.0) 0.048 (1.1) 2.0167 (4.7)
Total PlsEtn Sum 42.660 (100) 4.173 (100) 42.870 (100)
Absolute signal intensities of the various plasmalogen species measured in CHO, NRel-4 cells, and HEK293 cell lines. Values in brackets are 
the percentage of total PlsEtn sum.
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Figure 3 Plasmalogen biosynthetic pathway showing therapeutic intervention.
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Page 9 of 175. Free DHA had a slight impact on free cholesterol 
(14% reduction) compared to control, while it exhib-
ited a 24% increase in the esterified cholesterol frac-
tion at the 20 μM concentration.
6. Pravastatin treatments were most potent in reduc-
ing free cholesterol at 10 μM concentration (24% 
reduction compared to control, p = 0.01), while the 
100 μM concentration did not result in a further 
reduction of free cholesterol. The changes observed 
in the esterified cholesterol were not significant.
7. Treatments with PPARα (clofibrate; 100 and 200 
μM) and PPARγ (troglitazone; 1 and 10 μM) agonists 
had no impact on the cholesterol profile of HEK293 
cells at the concentrations tested.
Effect of PUFA-PlsEtn enhancement and HMG-CoA 
inhibition on cellular SOAT1 levels
The effects of the potent cholesterol esterification
enhancing/total cholesterol lowering PlsEtn precursor,
C1,and of the potent HMG-CoA reductase inhibiting/
total cholesterol lowering statin, pravastatin, on the basal
levels of cholesterol processing enzyme SOAT1 was
determined. The maximum cholesterol-lowering concen-
tration of C1, resulted in a 50% elevation of SOAT1 levels
(calculated using ImageJ software), whereas the maxi-
mum cholesterol-lowering concentration of pravastatin
had no effect on SOAT1 levels (Figure 10).
Discussion
Plasmalogens are major structural and functional lipids of
the cell. The discovery of this class of molecules was
made originally in myelin by Feulgen and Voit in 1924
[52], but the accurate structure of plasmalogens was
deduced only several years later [53,54]. The biological
function of plasmalogens, and their implication in dis-
eases remained elusive for a number of years until a
recent spike in interest in these lipids. In this report we
discuss the interplay between plasmalogens and choles-
terol, and investigate a plasmalogen restoration approach
in vitro.
The plasma membrane is the major storage location of
free cholesterol in that 80 to 95% of total cellular choles-
terol is found there, dependent upon cell type [55-58].
Excess cholesterol is transported out of peripheral cells
via HDL proteins following esterification in the mem-
brane and back to the liver via a process called reverse
transport [59,60]. Within the cell, cholesterol is trans-
ported from the plasma membrane to other cellular com-
partments via LDL after esterification within the
membrane [61,62].
PlsEtn deficient cells have been previously shown to
have impaired HDL-mediated cholesterol efflux [38] and
impaired intracellular LDL-mediated transport [39]. In
both of these studies normal functionality was observed
by either PlsEtn precursor treatment [38] or re-instate-
Figure 4 Side chain-specific restoration of PlsEtn in NRel-4 cells. Effect of C1, C2, C3, C6-10 treatment of NRel-4 (N_V) cells on sn-1 specific PlsEtn 
pools.
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Figure 5 Sn-2 rearrangement following C1, C2, C3, C6-10 treatment of NRel-4 (N_V) cells. Relative distribution of sn-2 fatty acids within each 
plasmalogen pool following treatments as above is displayed. All PlsEtn measurements are reported relative to the control CHO cells (C_V). Results 
are an average of three independent experiments. Error bars represent standard deviation.
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Page 11 of 17ment of the PlsEtn biosynthesis pathway [39]. Our data is
consistent with these studies in that plasmalogen defi-
cient cells were observed to have reduced levels of esteri-
fied cholesterol and increased levels of free and total
cholesterol (Figure 8) in the membrane. We have
expanded upon these studies by investigating in greater
detail the effect of membrane PlsEtn speciation on mem-
brane cholesterol esterification. By using a PlsEtn defi-
cient cell model (NRel-4) we selectively restored different
PlsEtn species by treating the cells with different 1-alkyl-
2-acyl glycerols (PlsEtn precursors). A comparison
between precursors C1, C2, and C3 (which differ only in
Figure 6 Comparison of sn-2 fatty acid substitution (A) and sn-1bond type (B) on total DHA PlsEtn levels in NRel-4 cells. NRel-4 cells were 
treated with ethanol solvent (N_V), or with test compounds at 20 μM concentration. Compounds C1, C6-10 contain palmityl ether at sn-1 and differ-
ent fatty acid moieties at sn-2 position; DHA (C1), oleic acid (C7), linoleic acid (C8), linolenic acid (C9), and arachidonic acid (C10), -OH refers to a free 
hydroxyl group at sn-2 position. Compounds C4 and C5 have acyl linkages at sn-1 and sn-2 positions. Total DHA containing ethanolamine plasmalo-
gens were quantified, and expressed relative to the amount observed in wild-type CHO cells (C_V). Values were an average of three independent ex-
periments. Error bars represent standard deviation.
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Page 12 of 17the sn-1 fatty acid) revealed that the sn-1 substituent
affected rearrangement at sn-2 position (Figure 5), and
hence the downstream restoration of plasmalogens. This
effect could be explained on the basis of stability of the
compounds. The DHA moiety in C2 is possibly more
labile (compared with C1 and C3) due to the steric hin-
drance caused by 18:0 fatty acid at sn-1 position.
These structure activity relationships revealed that
changes in membrane PUFA-PlsEtn levels are principally
responsible for the observed cholesterol effect (Figure 8)
and that restoration of membrane PUFA-PlsEtn levels
restores cholesterol homeostasis. The effect of membrane
PlsEtn modification using 1-alkyl-2-acyl glycerol PlsEtn
precursors on membrane cholesterol homeostasis was
further investigated using a human cell line (HEK293)
with normal PlsEtn biosynthetic machinery. PlsEtn pre-
cursor C1 concentration-dependently increased mem-
brane esterified cholesterol (Figure 9C) and decreased
free and total cholesterol (Figure 9A, B). Additionally,
PUFA-PlsEtn precursors were observed to be approxi-
mately twice as effective as statins at lowering cholesterol
levels. Treatment of the cells with DHA showed a slight,
yet significant reduction in free cholesterol in agreement
with the literature [63]. These results, in combination
with the detailed study of Munn and coworkers [39]
strongly indicate that PUFA-PlsEtn precursors reduce
membrane cholesterol levels via increased membrane
cholesterol esterification and transport. While it is true
Figure 7 Concentration response curve of PlsEtn precursor C1 in CHO and NRel-4 cells. Treatments were carried out at concentrations of 1 μM, 
5 μM, and 20 μM of C1. (A): Relative restoration/augmentation of DHA PlsEtn; (B): Relative restoration/augmentation of total PlsEtn. Values were nor-
malized to control CHO cells (C_V). Results are an average of three independent experiments. Error bars indicate standard deviation.
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Figure 8 Cholesterol profile of CHO/NRel-4 cells. Cholesterol profile of NRel-4 cells following 48 hour treatments with PlsEtn precursors (C1, C6-10) 
and PtdEtn precursors (C4, C5) compared to control CHO cells. A: total cholesterol; B: free cholesterol; C: esterified cholesterol. Cholesterol is reported 
as μg per million cells. Results are an average of three independent experiments. Asterisk represents values that are significantly different from those 
observed in DHAPAT-deficient NRel-4 cells (p < 0.05).
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Figure 9 Cholesterol profile of HEK293 cells treated for 48 hr with plasmalogen precursors. Cholesterol (total, free and esterified) content is 
reported as μg/million cells, and is an average of two independent experiments. Error bars indicate standard deviation. Asterisk indicates significantly 
lower total or free cholesterol, or significantly higher esterified cholesterol compared with control.
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Page 15 of 17that treatment of cells with PUFA-PlsEtn results in
greater esterification of cholesterol, it is not expected to
result in conditions similar to those in cholesterol ester
storage diseases, Cholesterol storage disease is caused by
lesions in the gene encoding lysosomal acid lipase. In
conditions where the lysosomal enzyme is intact, it is
expected that the cholesterol esters would be efficiently
packed into high density lipoprotein complexes to form
HDL-cholesterol for reverse cholesterol transport.
The observed increase in cholesterol esterification is
suggested to be due to elevated SOAT1, an enzyme
expressed in liver cells and macrophages which is
involved in cholesterol homeostasis (Figure 10). These
observations explain the increase in esterified cholesterol
and an elevated rate of HDL-mediated cholesterol efflux
reported by others [38,39]. These effects could not be
reproduced by either PPAR agonists or by HMG-CoA
reductase antagonists indicating that membrane PUFA-
PlsEtn enhancement is a novel mechanism for lowering
membrane cholesterol levels.
It is prudent to note that ACAT inhibition was thought
to be a promising pharmaceutical target for controlling
hypercholesterolemia. Several ACAT inhibitors entered
clinical trials, only to emerge with disappointing results.
Avasimibe and pactimibe treatment did not hamper the
progression of coronary atherosclerosis [64,65]. On the
contrary, in both trials the ACAT inhibitors resulted in a
significant elevation in LDL cholesterol over the placebo
arm, prompting an early termination of the trials. Addi-
tionally, in pactimibe trials, the treatment groups showed
a significant increase in atheroma volume in the coronary
artery [64], and significant increase in carotid intima-
media thickness compared to the placebo group [66].
These data question the strategy of ACAT inhibition in
treating hypercholesterolemia. Our data on the other
hand suggests that an increase in SOAT1 expression is
key to the formation of cholesterol esters (and reduction
in free cholesterol) prior to HDL mediated cellular cho-
lesterol efflux.
In summary, using a series of 1-alkyl-2-acylglycerols,
we showed that membrane PlsEtn levels can be selectively
restored in a PlsEtn deficient system and selectively aug-
mented in PlsEtn normal cells in a concentration-depen-
dent manner. Accordingly, these results represent the
first report of selective plasmalogen enhancement in nor-
mal cells. The structure activity relationship study sug-
gests that selective PUFA-PlsEtn enhancement is capable
of beneficially favoring cholesterol esterification, an obli-
gate step prior to efflux from the cell. This translates to a
net reduction in the fraction of free cholesterol in cells.
Plasmalogen restoration/enhancement therefore offers a
novel mechanism of cholesterol reduction in vitro.
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